The Sarcopenia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Sarcopenia Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sarcopenia Market.
Some of the key takeaways from the Sarcopenia Pipeline Report:
- Companies across the globe are diligently working toward developing novel Sarcopenia treatment therapies with a considerable amount of success over the years.
- Sarcopenia companies working in the treatment market are NMD Pharma, Turn Biotechnologies, Oncocross, Biophytis, MyMD Pharmaceuticals, and others, are developing therapies for the Sarcopenia treatment
- Emerging Sarcopenia therapies in the different phases of clinical trials are- NMDP 05, TRN 005, OC514, BIO101, MYMD-1, and others are expected to have a significant impact on the Sarcopenia market in the coming years.
- In July 2023, SARA-31, which is anticipated to be the first Phase II trial on sarcopenia, will be launched by Biophytis after receiving FDA approval.
- In February 2023, A 12-week resistance training programme with or without an oral nutritional supplement is the subject of a clinical trial that was launched at University College Dublin to examine its effectiveness.
Muscle mass, strength, and performance are severely hampered with age in sarcopenia, a musculoskeletal condition. The aged, sedentary people, and those with comorbidities that have an impact on the musculoskeletal system or limit physical exercise are the groups most frequently affected by sarcopenia.
Get a Free Sample PDF Report to know more about Sarcopenia Pipeline Therapeutic Assessment-
Emerging Sarcopenia Drugs Under Different Phases of Clinical Development Include:
- NMDP 05: NMD Pharma
- TRN 005: Turn Biotechnologies
- OC514: Oncocross
- BIO101: Biophytis
- MYMD-1: MyMD Pharmaceuticals
Sarcopenia Route of Administration
Sarcopenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Sarcopenia Molecule Type
Sarcopenia Products have been categorized under various Molecule types, such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Gene therapy
Sarcopenia Pipeline Therapeutics Assessment
- Sarcopenia Assessment by Product Type
- Sarcopenia By Stage and Product Type
- Sarcopenia Assessment by Route of Administration
- Sarcopenia By Stage and Route of Administration
- Sarcopenia Assessment by Molecule Type
- Sarcopenia by Stage and Molecule Type
DelveInsight’s Sarcopenia Report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Sarcopenia product details are provided in the report. Download the Sarcopenia pipeline report to learn more about the emerging Sarcopenia therapies
Some of the key companies in the Sarcopenia Therapeutics Market include:
Key companies developing therapies for Sarcopenia are – Sanofi SA, Bayer AG, GSK PLC, Metagenics LLC, Nestlé SA, and others.
Sarcopenia Pipeline Analysis:
The Sarcopenia pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Sarcopenia with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sarcopenia Treatment.
- Sarcopenia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Sarcopenia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sarcopenia market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Sarcopenia drugs and therapies
Sarcopenia Pipeline Market Drivers
- Increase in Prevalence of Sarcopenia, increase in Research and development activities are some of the important factors that are fueling the Sarcopenia Market.
Sarcopenia Pipeline Market Barriers
- However, complications of Sarcopenia treatment, lack of awareness about the disease and other factors are creating obstacles in the Sarcopenia Market growth.
Scope of Sarcopenia Pipeline Drug Insight
- Coverage: Global
- Key Sarcopenia Companies: NMD Pharma, Turn Biotechnologies, Oncocross, Biophytis, MyMD Pharmaceuticals, and others
- Key Sarcopenia Therapies: NMDP 05, TRN 005, OC514, BIO101, MYMD-1, and others
- Sarcopenia Therapeutic Assessment: Sarcopenia current marketed and Sarcopenia emerging therapies
- Sarcopenia Market Dynamics: Sarcopenia market drivers and Sarcopenia market barriers
Request for Sample PDF Report for Sarcopenia Pipeline Assessment and clinical trials
Table of Contents
1. Sarcopenia Report Introduction
2. Sarcopenia Executive Summary
3. Sarcopenia Overview
4. Sarcopenia- Analytical Perspective In-depth Commercial Assessment
5. Sarcopenia Pipeline Therapeutics
6. Sarcopenia Late Stage Products (Phase II/III)
7. Sarcopenia Mid Stage Products (Phase II)
8. Sarcopenia Early Stage Products (Phase I)
9. Sarcopenia Preclinical Stage Products
10. Sarcopenia Therapeutics Assessment
11. Sarcopenia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Sarcopenia Key Companies
14. Sarcopenia Key Products
15. Sarcopenia Unmet Needs
16 . Sarcopenia Market Drivers and Barriers
17. Sarcopenia Future Perspectives and Conclusion
18. Sarcopenia Analyst Views
20. About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Address:27 Drydock Ave S. Jones Blvd #2432
Country: United States